Resistell’s first patients recruited for international clinical study
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue readingInnovation, Investment, Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
New Year’s resolutions can be a powerful way to make positive changes in life and achieve goals.
Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.